Eli Lilly halts COVID-19 antibody-treatment trial over ‘safety concern’

Eli Lilly halts COVID-19 antibody-treatment trial over ‘safety concern’


The testing of a possible antibody treatment for COVID-19 by drug giant Eli Lilly has been put on hold over a “potential safety concern,’’ a report said Tuesday.

Officials involved in the government-sponsored, late-stage clinical trials e-mailed testing researchers saying the program had been halted because a participant fell ill, according to the New York Times.

“Safety is of the utmost importance to Lilly,’’ company rep Molly McCully wrote The Post in an e-mail Tuesday.

Trending: 'Seinfeld' Cast Members Pushing Fundraising Effort to Turn Texas Blue: 'Texas Has Never Been a Red State'

“We are aware that, out of an abundance of caution, the ACTIV-3 independent data safety monitoring board (DSMB) has recommended a pause in enrollment,’’ the rep said, referring to the group of clinical-research experts that helps the government oversee such trials.

“The trial, evaluating Lilly’s investigational neutralizing antibody as a treatment for COVID-19 in hospitalized patients, is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH),’’ McCully said.

“Lilly is supportive of the decision

Continue reading

You Might Like

Do NOT follow this link or you will be banned from the site!